Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038 QTORIN™ rapamycin has ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the presentation of its investigational therapy QTORIN™ ...

Also known as sirolimus or Rapamune, rapamycin inhibits the activity of a protein called mTOR, which helps regulate cell growth and metabolism. Suppressing mTOR seems to weaken inflammation and ...

The drug blocks the activity of a protein known as mammalian target of rapamycin (mTOR), which promotes proliferation through the activation of proteins such as S6 kinase. Although the mTOR ...

In particular, the mechanistic target of rapamycin (mTOR) pathway has been tied to multiple age-related chronic disease processes, such as declining immune function, diminishing bone mineral ...

The protein was actually named after the drug: mTOR stands for mechanistic target of rapamycin. This was all 25 to 30 years ago. In the intervening couple of decades, we have learned that mTOR is a ...

About Microcystic Lymphatic Malformations Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of ...

The granted patent “Anhydrous Compositions of mTOR Inhibitors and Methods of Use” broadens protection for QTORIN™ rapamycin and the conditions related to its use in clinical indications ...